Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients.
Myasthenia gravis (MG) is an autoimmune disorder with heterogeneity. Antibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK), titin and ryanodine receptor (RyR) were examined in 437 adult Chinese MG patients. The AChR, MuSK, titin and RyR antibodies were found in 82.2%, 2.3%, 28.4% and 23.8% of all patients. Autoantibody profiles vary among different MG subgroups. Thymoma MG patients had high frequencies of AChR (99.2%), titin (50.8%) and RyR antibodies (46.9%). The titin and RyR antibodies also showed high frequencies in late onset patients (54.4% and 33.3%, respectively). These two antibodies may indicate an underlying thymoma when combined. The patients with titin and RyR antibodies tend to have more severe disease and worse outcome, and may need more active immunosuppressive treatment.
Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Yu
Y
Hong
Department of Neurology, Qilu Hospital of Shandong University, Jinan, China.
Hai-Feng
HF
Li
Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Geir Olve
GO
Skeie
Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Fredrik
F
Romi
Department of Neurology, Peking University First Hospital, Beijing, China.
Hong-Jun
HJ
Hao
Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Xu
X
Zhang
Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China.
Xiang
X
Gao
Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Jone Furlund
JF
Owe
Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Neurology, Haukeland University Hospital, Bergen, Norway. Electronic address: nils.gilhus@helse-bergen.no.
Nils Erik
NE
Gilhus
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001323:Autoantibodies / Q000378:metabolism*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications / Q000276:immunology*; D011863:Radioimmunoassay; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology*; D011950:Receptors, Cholinergic / Q000276:immunology*; D012189:Retrospective Studies; D019837:Ryanodine Receptor Calcium Release Channel / Q000276:immunology*; D012720:Severity of Illness Index; D000089804:Shelterin Complex; D034501:Telomere-Binding Proteins / Q000276:immunology; D013945:Thymoma / Q000150:complications / Q000276:immunology; D055815:Young Adult
C495876:ACD protein, human; D001323:Autoantibodies; D011950:Receptors, Cholinergic; D019837:Ryanodine Receptor Calcium Release Channel; D000089804:Shelterin Complex; D034501:Telomere-Binding Proteins; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases
Muscle-specific kinase antibodies; Myasthenia gravis; Ryanodine receptor antibodies; Thymoma; Titin antibodies